Gyre Therapeutics, Inc. (GYRE)
(Real Time Quote from BATS)
$13.75 USD
+0.57 (4.33%)
Updated Aug 29, 2024 03:35 PM ET
After-Market: $13.41 -0.34 (-2.47%) 4:18 PM ET
3-Hold of 5 3
D Value A Growth C Momentum B VGM
Cash flow Statements
Fiscal Year End for Gyre Therapeutics, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -85.48 | -8.24 | -87.93 | -56.24 | -55.18 |
Depreciation/Amortization & Depletion | 1.11 | 0.23 | 0.29 | 0.14 | 0.15 |
Net Change from Assets/Liabilities | 7.46 | -4.95 | 0.48 | -2.57 | 8.22 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 102.80 | -20.14 | 3.41 | 3.63 | 3.20 |
Net Cash From Operating Activities | 25.89 | -33.10 | -83.76 | -55.05 | -43.61 |
Property & Equipment | -7.85 | 0.50 | -0.84 | -0.27 | -0.06 |
Acquisition/ Disposition of Subsidiaries | -0.12 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | -1.00 | 2.50 | 49.03 | 9.93 | 27.46 |
Other Investing Activities | -10.78 | 52.42 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | -19.76 | 55.43 | 48.19 | 9.66 | 27.39 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 2.50 | 0.02 | 49.55 | 60.38 | 0.33 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | -45.03 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Financing Activities | 2.50 | -45.01 | 49.55 | 60.38 | 0.33 |
Effect of Exchange Rate Changes | -0.30 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | 8.33 | -22.68 | 13.99 | 14.99 | -15.89 |
Cash at Beginning of Period | 25.18 | 44.35 | 30.36 | 15.37 | 31.26 |
Cash at End of Period | 33.51 | 21.67 | 44.35 | 30.36 | 15.37 |
Diluted Net EPS | -1.41 | -3.90 | -43.03 | -43.93 | -68.97 |
Fiscal Year End for Gyre Therapeutics, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | 14.47 | 9.94 | -85.48 | -3.79 | -2.21 |
Depreciation/Amortization & Depletion | 0.66 | 0.43 | 1.11 | 0.00 | 0.00 |
Net Change from Assets/Liabilities | -10.14 | -2.76 | 7.46 | -3.78 | -2.04 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | -7.60 | -4.72 | 102.80 | -4.34 | -4.44 |
Net Cash From Operating Activities | -2.61 | 2.88 | 25.89 | -11.90 | -8.69 |
Property & Equipment | -1.42 | -0.18 | -7.85 | 0.00 | 0.00 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | -0.12 | 0.00 | 0.00 |
Investments | 0.00 | 0.00 | -1.00 | 0.00 | 0.00 |
Other Investing Activities | -14.07 | -7.04 | -10.78 | 5.21 | 5.21 |
Net Cash from Investing Activities | -15.49 | -7.22 | -19.76 | 5.21 | 5.21 |
Uses of Funds
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 0.93 | 0.66 | 2.50 | 0.02 | 0.00 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | -12.76 | -11.26 |
Other Financing Activities | -0.12 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Financing Activities | 0.81 | 0.66 | 2.50 | -12.74 | -11.26 |
Effect of Exchange Rate Changes | -0.12 | -0.05 | -0.30 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | -17.41 | -3.72 | 8.33 | -19.44 | -14.74 |
Cash at Beginning of Period | 33.51 | 33.51 | 25.18 | 21.67 | 21.67 |
Cash at End of Period | 16.10 | 29.79 | 33.51 | 2.23 | 6.92 |
Diluted Net EPS | 0.01 | 0.03 | 0.09 | -0.60 | -1.05 |